SAN DIEGO, Nov. 14, 2016 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), today will hold a conference call after the U.S. financial markets close to discuss third quarter financial results and interim safety and imaging results from phase I clinical trials in HuMab-5B1 antibody development programs. Below are details for the call.
Conference Call Information
When: November 14, 2016, 4:15 p.m. ET
Dial-in: (877) 407-8293 or (201) 689-8349
Conference ID: MabVax Therapeutics Third Quarter 2016 Conference Call
Please join the conference call at least 10 minutes early to register. A replay of the conference call will be available for 2 weeks shortly after the call. To access the replay, please dial 877-660-6853 or 201-612-7415. Conference ID: 13649739.
About MabVax Therapeutics Holdings, Inc.
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been vaccinated against targeted cancers with the Company’s proprietary vaccines. MabVax’s HuMab-5B1 antibody is fully human and was discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase I trial at Memorial Sloan Kettering Cancer Center, or MSK. The antigen the antibody targets is expressed on more than 90% of pancreatic cancers making the antibody potentially broadly applicable to most patients suffering from this type of cancer. Additional information is available at www.mabvax.com.
Contact:
Robert Haag, Managing Director
IRTH Communications
MBVX@irthcommunications.com
1-866-976-4784
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mabvax-therapeutics-to-hold-conference-call-to-provide-corporate-update-on-monday-november-14-2016-300362307.html
SOURCE MabVax Therapeutics Holdings, Inc.
